Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study

Myasthenia gravis (MG) is an autoimmune disorder with antibodies targeting the postsynaptic endplate leading to fluctuating muscle weakness in extraocular, bulbar, limb, and axial muscles. Approximately 85% of MG patients are serum positive for anti-acetylcholine receptors (AChR) antibodies, while anti-muscle-specific kinase (MuSK) antibodies are detected in around 5-6% of all patients [1]. Thymoma-associated myasthenia gravis (TMG) is almost exclusively linked to AChR antibodies with a peak age of 50 years.

Source: Neuromuscular Disorders - September 22, 2023 Category: Neurology Authors: Xiao Huan, Zhe Ruan, Rui Zhao, Manqiqige Su, Fan Ning, Zhangyu Zou, Song Tan, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Qilong Jiang, Jianying Xi, Ting Chang, Sushan Luo, Chongbo Zhao, Pan-Yangtze River Delta Alliance for Neuromuscular Disorders (P Source Type: research